Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43846   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-004214-27
    Sponsor's Protocol Code Number:91554
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2008-11-14
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2008-004214-27
    A.3Full title of the trial
    Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen for 13 cycles in 1650 healthy female subjects
    A.3.2Name or abbreviated title of the trial where available
    EU/LA/AUS Pearl Index study – transdermal contraceptive patch
    A.4.1Sponsor's protocol code number91554
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer Healthcare AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFC Patch Low
    D.3.2Product code material no. 80876395
    D.3.4Pharmaceutical form Transdermal patch
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPTransdermal use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNETHINYLESTRADIOL
    D.3.9.1CAS number 57-63-6
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.55
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGESTODENE
    D.3.9.1CAS number 60282873
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    The primary objective of this study is to investigate the contraceptive efficacy of the transdermal contraceptive patch (material no. 80876395).
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level PT
    E.1.2Classification code 10060346
    E.1.2Term Transdermal contraception
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to investigate the contraceptive efficacy of the transdermal contraceptive patch (material no. 80876395).
    E.2.2Secondary objectives of the trial
    The secondary objectives are bleeding pattern, cycle control and safety profile. Compliance and subjective assessment of satisfaction with the transdermal contraceptive patch will also be evaluated as secondary objectives.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signed and dated informed consent
    2. Healthy female subject requesting contraception
    3. Age: 18 – 35 years (inclusive); smokers must not be older than 30 years at the
    time of informed consent
    4. Normal cervical smear not requiring further follow-up (a cervical smear has to be
    taken at screening visit or a normal result has to be documented within the
    previous 6 months)
    5. History of regular cyclic menstrual periods
    E.4Principal exclusion criteria
    1. Pregnancy or lactation (less than 3 menstrual cycles before start of treatment)
    2. Obesity (Body Mass Index > 30.0 kg/m2)
    3. Hypersensitivity to any ingredient of the study drug
    4. Significant skin reaction to transdermal preparations or sensitivity to surgical/
    medical tape
    5. Any diseases or conditions that can compromise the function of the body systems
    and could result in altered absorption, excessive accumulation, impaired
    metabolism, or altered excretion of the study drug (e.g., known skin disease with
    suspected alteration of dermal absorption or poor adherence of the patch such as
    psoriasis)
    6. Any diseases or conditions that might interfere with the conduct of the study or
    the interpretation of the results
    7. Any disease or condition that may worsen under hormonal treatment such as:
    Cardiovascular
    - presence or a history of venous or arterial thrombotic/thromboembolic events
    (e.g., deep venous thrombosis, pulmonary embolism, myocardial infarction) or of
    a cerebrovascular accident, including prodromi (e.g., transient ischaemic attack,
    angina pectoris) and conditions that could increase the risk to suffer from any of
    the above mentioned disorders, e.g., a family history indicating a hereditary
    predisposition
    - repeated measurements of systolic blood pressure > 140 mm Hg and/or diastolic
    blood pressure > 90 mm Hg
    Liver
    - presence or history of liver tumors (benign or malignant)
    - presence or history of severe hepatic disease as long as liver function values
    have not returned to normal
    - jaundice and/or pruritus related to cholestasis (Gilbert’s syndrome excepted)
    - history of cholestatic jaundice associated with pregnancy or previous COC use
    Metabolic diseases
    - uncontrolled diabetes mellitus and/or diabetes mellitus with vascular
    involvement
    - severe dyslipoproteinemia
    Other diseases
    - malignant or premalignant disease
    - uncontrolled thyroid disorder
    - severe renal insufficiency or acute renal failure
    - history of hypertriglyceridemia-associated pancreatitis
    - pemphigoid gestationis during a previous pregnancy
    - history of herpes gestationis
    - otosclerosis-related hearing loss
    - history of migraine with focal neurologic symptoms
    - epilepsy
    - clinically significant depression
    - hereditary angioedema
    8. Undiagnosed abnormal genital bleeding
    9. Abuse of alcohol, drugs, or medicines (e.g., laxatives)
    10. Other contraceptive methods:
    - sterilization
    - oral, vaginal, or transdermal hormonal contraception during treatment
    - intrauterine devices (IUDs) with or without hormone release
    - implants
    - long-acting preparations (e.g., Depot-MPA, monthly contraceptive injection)
    within a period of 3 times of the injection interval before start of treatment.
    11. Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug or interfere with the conduct of the study or the interpretation of the results such as:
    - products containing St. John’s wort (Hypericum perforatum)
    - antibiotics (except for short-term treatment)
    - anticoagulants (e.g., heparin, coumarin)
    - antiepileptics (hydantoin derivatives [e.g., phenytoin] or carboxamide derivatives
    [e.g., carbamazepine, oxcarbamazepine], others [e.g., felbamate, topiramate])
    - hypnotics and sedatives (e.g., barbiturate derivatives, primidone)
    - tuberculostatics (e.g., rifampicin)
    - oral antimycotics (e.g., griseofulvin, ketoconazole, itraconazole, fluoconazole)
    (except for single shot treatment)
    - virostatic agents (except for topical use [e.g., ritonavir])
    - phenylbutazone
    - additional sex steroids and other drugs impairing ovarian function
    12. Simultaneous participation in another clinical trial or participation in another
    clinical trial prior to study entry that might have an impact on the study
    objectives, at the discretion of the investigator
    13. Major surgery scheduled during the study period
    14. Subject is a dependent person (e.g., a family member or member of the
    investigator’s staff)
    15. Inability to cooperate with the study procedures for any reason, including the
    following examples: language comprehension, psychiatric illness, inability to get
    to the study site.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable is the occurrence of pregnancy (yes/no) while on treatment up to 7 days after removal of the last patch, assessed by the Pearl Index and life table analysis.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Information not present in EudraCT
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Information not present in EudraCT
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    In compliance with EU regulations, the end of the study (EOS) is defined as the last visit of the last patient. This includes any unscheduled visits, if applicable.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2008-11-14. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state317
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1150
    F.4.2.2In the whole clinical trial 1650
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2009-04-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-04-21
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 12:05:00 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA